CARDIFF ONCOLOGY INC
NASDAQ: CRDF (Cardiff Oncology, Inc.)
Kemas kini terakhir: 2 jam lalu1.91
0.21 (12.35%)
| Penutupan Terdahulu | 1.70 |
| Buka | 1.75 |
| Jumlah Dagangan | 2,431,136 |
| Purata Dagangan (3B) | 1,214,996 |
| Modal Pasaran | 128,658,664 |
| Harga / Jualan (P/S) | 225.55 |
| Harga / Buku (P/B) | 2.38 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 May 2026 |
| Margin Operasi (TTM) | -13,194.49% |
| EPS Cair (TTM) | -0.930 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -46.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.91% |
| Nisbah Semasa (MRQ) | 6.22 |
| Aliran Tunai Operasi (OCF TTM) | -42.75 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -25.76 M |
| Pulangan Atas Aset (ROA TTM) | -41.00% |
| Pulangan Atas Ekuiti (ROE TTM) | -74.15% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Cardiff Oncology, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | -1.5 |
| Osilator Teknikal | -4.0 |
| Purata | -0.50 |
|
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 5.64% |
| % Dimiliki oleh Institusi | 45.29% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Laurion Capital Management Lp | 31 Dec 2025 | 2,646,738 |
| Acorn Capital Advisors, Llc | 31 Dec 2025 | 1,962,084 |
| Blair William & Co/Il | 31 Dec 2025 | 1,948,847 |
| Flputnam Investment Management Co | 31 Dec 2025 | 595,328 |
| Northern Trust Corp | 31 Dec 2025 | 461,753 |
| Candriam S.C.A. | 31 Dec 2025 | 344,437 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 10.00 (HC Wainwright & Co., 423.56%) | Beli |
| Median | 8.00 (318.85%) | |
| Rendah | 6.00 (Piper Sandler, 214.14%) | Beli |
| Purata | 8.00 (318.85%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 1.77 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Piper Sandler | 25 Feb 2026 | 6.00 (214.14%) | Beli | 1.91 |
| HC Wainwright & Co. | 28 Jan 2026 | 10.00 (423.56%) | Beli | 1.62 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 27 Jan 2026 | Pengumuman | Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC |
| 27 Jan 2026 | Pengumuman | Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development |
| 09 Dec 2025 | Pengumuman | Sidoti Events, LLC's Year-End Virtual Investor Conference |
| 08 Dec 2025 | Pengumuman | Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025 |
| 08 Dec 2025 | Pengumuman | Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |